erlotinib hydrochloride has been researched along with Erythremia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ | 1 |
| Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ | 1 |
| Li, Y; Ren, YY; Zhang, LY | 1 |
| Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ | 1 |
1 trial(s) available for erlotinib hydrochloride and Erythremia
| Article | Year |
|---|---|
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine | 2015 |
3 other study(ies) available for erlotinib hydrochloride and Erythremia
| Article | Year |
|---|---|
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2009 |
[Effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro].
Topics: Cell Differentiation; Cell Proliferation; Cells, Cultured; Erlotinib Hydrochloride; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Polycythemia Vera; Quinazolines | 2012 |
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine | 2007 |